A54.24
A54.24: Gonococcal female pelvic inflammatory disease
Billable / specific codeICD-10-CM
A54.24 is a billable, specific ICD-10-CM code for gonococcal female pelvic inflammatory disease. It is valid for submission on a claim.
Check A54.24 with the rest of the claim: free scrubberExcludes1: never code together
These conditions cannot occur together. Billing both on the same encounter is a denial.
- gonococcal peritonitis (A54.85)
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Gonococcal pelviperitonitis
Other codes that can never be billed with A54.24
Their own Excludes1 notes name this code, so the conflict is not listed above.
Risk adjustment
No CMS-HCC V28 category: this code does not change a RAF score.
Medicare coverage
A54.24 is named in 4 Medicare coverage policies: 4 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A58710Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58720Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58747Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58761Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Alphabetic index entries that lead here
- Endometritis›blennorrhagic(gonococcal) (acute) (chronic)
- Endometritis›gonococcal, gonorrheal(acute) (chronic)
- Gonococcus, gonococcal›fallopian tubes(acute) (chronic)
- Gonococcus, gonococcal›pelviperitonitis
- Gonococcus, gonococcal›pelvis(acute) (chronic)
- Gonococcus, gonococcal›pyosalpinx(acute) (chronic)
- Gonorrhea›fallopian tube(acute) (chronic)
- Gonorrhea›ovary(acute) (chronic)
- Gonorrhea›pelvis(acute) (chronic)
- Pelviperitonitis›gonococcal
- Salpingitis›gonococcal(acute) (chronic)
- Salpingitis›specific(gonococcal) (acute) (chronic)
Code history
Unchanged in every release from FY2024 to FY2027.